





<b>AMENDMENT TRANSMITTAL LETTER (Large Entity)</b>				Docket No. <b>PG3602USW</b>	
Applicant(s): <b>Campbell et al.</b>					
Serial No. <b>09/830,836</b>	<b>AUG 3 2002</b>	Filing Date <b>May 1, 2001</b>	Examiner <b>B. Robinson</b>	Group Art Unit <b>1625</b>	
Invention: <b>Pyrazolopyridine Derivatives as Selective COX-2 Inhibitors</b>					
<u>TO THE ASSISTANT COMMISSIONER FOR PATENTS:</u>					
Transmitted herewith is an amendment in the above-identified application. The fee has been calculated and is transmitted as shown below.					
<b>CLAIMS AS AMENDED</b>					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	31 -	31 =	0 x	\$18.00	\$0.00
INDEP. CLAIMS	5 -	5 =	0 x	\$84.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
<b>TOTAL ADDITIONAL FEE FOR THIS AMENDMENT</b>					<b>\$0.00</b>
<input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ A duplicate copy of this sheet is enclosed. <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. <b>07-1392</b> A duplicate copy of this sheet is enclosed. <input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17.					
 Signature			Dated: <b>13 Aug 2002</b>		
Lorie Ann Morgan, Reg. No. 38,181					
 <b>23347</b> PATENT TRADEMARK OFFICE			I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.  _____ Signature of Person Mailing Correspondence  _____ Typed or Printed Name of Person Mailing Correspondence		
CC:					


**RECEIVED**  
**AUG 19 2002**  
**TECH CENTER 1600/2900**

08-14-02

981625

<b>CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)</b>		<b>Docket No.</b> PG3602USW	
Applicant(s): Campbell et al.		Group Art Unit 625	
Serial No. 09/830,836	Mailing Date May 1, 2001	Examiner B. Robinson	
Invention: Pyrazolopyridine Derivatives as Selective COX-2 Inhibitors			
<p>I hereby certify that this <u>Response to office action with accompanying reference</u> (Identify type of correspondence)</p> <p>is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: The Commissioner of Patents and Trademarks, Washington, D.C. 20231-0001 on <u>August 13, 2002</u> (Date)</p> <p><u>Valerie L. Phillips</u> (Typed or Printed Name of Person Mailing Correspondence)</p> <p><u>Valerie L. Phillips</u> (Signature of Person Mailing Correspondence)</p> <p><u>EV022190346US</u> (Express Mail Mailing Label Number)</p>			





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application:

I. Campbell et al.,

Serial No.: 09/830,836

Examiner: B. Robinson

Filing Date: 1 May 2001

Art Unit: 1625

For: PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS

Commissioner of Patents  
Washington D.C. 20231

#13C  
n.n.  
20/25/02  
RECEIVED  
AUG 19 2002  
TECH CENTER 1600/2900

RESPONSE

Sir:


Responsive to the Office Action mailed 15 May 2002, please amend and reconsider the instant application in view of the following amendments and remarks.

Amendment

In the Claims:

Please amend claims 26-32 as follows. The following clean claims reflect the amendments being made herein. The following is a complete set of claims as pending after the instant amendment. A marked-up copy of the amended claims 26-32 is attached hereto.

1. (Twice Amended) A compound of formula (I)



and pharmaceutically acceptable derivatives thereof wherein